title: Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies.
abstract: OBJECTIVE
  Adoptive immunotherapy with the use of cytokine-induced killer (CIK) cells represents an effective therapeutic option for treating malignancies. The characteristics and function of cord blood-derived CIK (CB-CIK) cells have been evaluated both in vitro and in vivo. In this study, we assessed the efficacy and safety of administering CB-CIK cells to patients with cancer.
  
  
  METHODS
  In this retrospective clinical trial, 15 patients with cancer received CB-CIK therapy with different cycles from April 2012 to August 2014. CB-CIK cells demonstrated a high percentage of main functional fraction CD3(+)CD56(+) and efficient anti-tumor activity in vitro.
  
  
  RESULTS
  After the infusion of CB-CIK cells, the subsets of CD3(+)CD4(+) T lymphocytes and CD3(-)CD56(+) T cells in the peripheral blood were significantly increased compared with those before the therapy. Of 15 patients, one patient with hepatocellular cancer and one patient with esophageal cancer achieved complete responses, two patients with ovarian cancer obtained partial remissions, 10 patients had stable disease and one patient with hepatocellular cancer had progressive disease. Acute toxicities including fever, slight fever, dizziness and other neurologic toxicities were few and occurred in patients after infusion of CB-CIK cells.
  
  
  CONCLUSIONS
  These results demonstrated the feasibility and safety of treating malignancies with CB-CIK cells. The study provides a potential therapeutic approach for the patients with poor health or older patients who cannot tolerate repeated collection of blood.
authors.affiliation: Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Wang
authors.affiliation: Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Zhenzhen
authors.initials: Z
authors.lastname: Luo
authors.affiliation: Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Xuan
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Jianmin
authors.initials: J
authors.lastname: Huang
authors.affiliation: Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.affiliation: Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Shuangning
authors.initials: S
authors.lastname: Yang
authors.affiliation: Department of Obstetrics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Xianlan
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Obstetrics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Liuxia
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.affiliation: Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
authors.forename: Lan
authors.initials: L
authors.lastname: Huang
authors.affiliation: Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; School of Life Science, Zhengzhou University, Zhengzhou, Henan, China; Engineering Key Laboratory for Cell Therapy of Henan Province, Zhengzhou, Henan, China. Electronic address: yizhang@zzu.edu.cn.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D055612:Cytokine-Induced Killer Cells / Q000276:immunology / Q000637:transplantation*; D005260:Female; D005312:Fetal Blood / Q000166:cytology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D015703:Antigens, CD
keywords: cord blood; cytokine-induced killer cells; efficacy; malignancies; safety